

Collaborative Care for Depression

A Cumulative Meta-analysis and Review of Longer-term Outcomes

Simon Gilbody, MBChB, MRCPsych, DPhil; Peter Bower, PhD;
Janine Fletcher, MSc; David Richards, PhD; Alex J. Sutton, PhD

Background: Depression is common in primary care but is suboptimally managed. Collaborative care, that is, structured care involving a greater role of nonmedical specialists to augment primary care, has emerged as a potentially effective candidate intervention to improve quality of primary care and patient outcomes.

Methods: To quantify the short-term and longer-term effectiveness of collaborative care compared with standard care and to understand mechanisms of action by exploring between-study heterogeneity, we conducted a systematic review of randomized controlled trials that compared collaborative care with usual primary care in patients with depression. We searched MEDLINE (from the beginning of 1966), EMBASE (from the beginning of 1980), CINAHL (from the beginning of 1980), PsycINFO (from the beginning of 1980), the Cochrane Library (from the beginning of 1966), and DARE (Database of Abstracts of Reviews of Effectiveness) (from the beginning of 1985) databases from study inception to February 6, 2006.

Results: We found 37 randomized studies including 12 355 patients with depression receiving primary care.

Random effects meta-analysis showed that depression outcomes were improved at 6 months (standardized mean difference, 0.25; 95% confidence interval, 0.18-0.32), and evidence of longer-term benefit was found for up to 5 years (standardized mean difference, 0.15; 95% confidence interval, 0.001-0.31). When exploring determinants of effectiveness, effect size was directly related to medication compliance and to the professional background and method of supervision of case managers. The addition of brief psychotherapy did not substantially improve outcome, nor did increased numbers of sessions. Cumulative meta-analysis showed that sufficient evidence had emerged by 2000 to demonstrate the statistically significant benefit of collaborative care.

Conclusions: Collaborative care is more effective than standard care in improving depression outcomes in the short and longer terms. Future research needs to address the implementation of collaborative care, particularly in settings other than the United States.

Arch Intern Med. 2006;166:2314-2321

DEPRESSION IS SOON TO BECOME the second leading cause of disability worldwide.¹ It affects between 5% and 10% of individuals and is the third most common reason for consultation in primary care.² Management falls below accepted evidence-based standards,^{3,4} and the enhanced management of depression in primary care is

*For editorial comment
see page 2304*

Author Affiliations:
Department of Health Sciences, University of York, York (Drs Gilbody and Richards); National Primary Care Research and Development Centre (Dr Bower) and School of Nursing and Midwifery (Ms Fletcher), University of Manchester, Manchester; and Department of Health Sciences, University of Leicester, Leicester (Dr Sutton); England.

central to the World Health Organization strategy for mental health.⁵ Many organizational and educational strategies targeted at health care professionals have been proposed to improve the recognition and management of depression in primary care.⁶ These include the following: educational strategies, such as guidelines, targeted at health care professionals⁷; consultation-liaison, with an educative role for

practitioners working more closely with nonspecialist clinicians⁸; and collaborative care involving a structured approach

*CME course available at
www.archinternmed.com*

to care based on chronic disease management principles and a greater role for nonmedical specialists such as nurse practitioners working in conjunction with the primary care physician and a mental health specialist.⁹

Previous reviews of management of depression have identified collaborative care as the most effective of these approaches.^{6,10-14} However, there are important limitations to these published reviews. Some reviews have pooled heterogeneous studies with only limited exploration of important causes of heterogeneity¹³ and others have omitted important studies because of the inadequacy of search

strategies.¹⁴ In addition, substantial evidence has emerged in recent years capturing the longer-term outcome of these interventions.¹⁵ Collaborative care is an active area of research, and previous reviews are substantially out of date.¹²⁻¹⁴

Collaborative care captures a range of interventions of varying intensity, ranging from simple telephone interventions to encourage compliance with medication¹⁶ to more complex interventions that involve intensive follow-up and incorporate a form of structured psychosocial intervention.¹⁷ Such study-level design variables might be related to the overall effectiveness of a collaborative care program. Similarly, collaborative care has generally been developed in the United States within managed health care settings, and the overall effectiveness of collaborative care programs might vary when it is implemented and evaluated in non-US settings. It remains unclear, therefore, just how effective collaborative care is and what the important determinants of effectiveness are. Identifying the magnitude of clinical effectiveness and the important determinants of effect is vital for those who plan services and might implement collaborative care.

Our purpose was to explore the totality of randomized research into collaborative care in more detail and with more rigor than has been done previously, to establish the clinical effectiveness of collaborative care during both the short- and longer-terms, important determinants of effectiveness of collaborative care, and how research has evolved with time and the totality of research evidence in this area.

METHODS

LITERATURE SEARCH AND INCLUSION CRITERIA

We searched a variety of biomedical, nursing, and psychological databases from study inception to February 6, 2006, including MEDLINE (from the beginning of 1966), EMBASE (from the beginning of 1980), CINAHL (from the beginning of 1980), PsycINFO (from the beginning of 1980), the Cochrane Library (from the beginning of 1966), and DARE (Database of Abstracts of Reviews of Effectiveness) (from the beginning of 1980). We also scrutinized reference lists of studies and used citation searching for all studies that met our inclusion criteria.

We included randomized controlled trials with patients with depression being managed in primary care settings using a collaborative care approach. For this review, collaborative care was broadly defined as a multifaceted intervention involving combinations of 3 distinct professionals working collaboratively within the primary care setting⁹: a case manager, a primary care practitioner, and a mental health specialist. To be included, studies had to involve 2 of these 3 components of collaborative care.

OUTCOMES

We analyzed short-term (6 months) and longer-term (12, 18, and 24 months, and 5 years) outcomes in both collaborative care and standard care groups. We sought to standardize outcomes between studies, specifically by seeking data on depression outcomes and antidepressant medication concordance. We analyzed both of these variables at the point closest to 6 months postrandomization. Collaborative care interventions often seek to improve concordance with antidepressant medication,¹¹ and we analyzed changes in measures of antidepressant use (eg, the

percentage of patients taking antidepressant medications or meeting standardized guidelines for antidepressant medication use).¹⁸ Where multiple outcomes were reported, we chose any identified primary outcome first, then prioritized observer-rated scales over self-report measures. We translated continuous measures to a standardized effect size (ie, mean of intervention group minus mean of control group divided by the pooled standard deviation). We translated outcomes reported as dichotomous variables to standardized effect size using the logit transformation.¹⁹

META-ANALYTIC POOLING AND MEASUREMENT OF HETEROGENEITY

We performed a random-effects meta-analysis.²⁰ Between-study heterogeneity was assessed using the I^2 statistic,²¹ which describes the percentage of total variation across studies that is the result of heterogeneity rather than chance. Publication bias was examined by constructing Begg funnel plots²² and by testing for funnel plot asymmetry using the Egger weighted regression test.²³ All statistical pooling was conducted using “metan” and “metabias” user-written commands in STATA version 8 (StataCorp, College Station, Tex).

CORRECTION FOR UNIT OF ANALYSIS ERROR

We identified all studies using cluster randomization and, where necessary, adjusted the precision of these studies in the meta-analysis using a sample size or variation inflation method²⁴ and assuming an intraclass correlation of 0.02, in line with published estimates.^{25,26}

EXPLORATION OF CAUSES OF HETEROGENEITY

We anticipated several sources of heterogeneity relating to the content of the intervention and fidelity to a collaborative care model; the health care setting, and the degree to which patients were concordant with medication within a collaborative care program. Predictive variables included fidelity to the collaborative care model, as defined by Katon et al⁹; study setting (US vs non-US); recruitment method (screening vs referral by clinicians); study population (unselected depressed patients vs depressed patients identified as willing to take medication); use of primary care physician training; case manager professional background; case manager supervision; addition of psychotherapy to standard case management; and number of case management sessions.

Where these were reported, in most studies, we explored the effect of these study-level variables on the overall effectiveness of collaborative care using sensitivity analyses and meta-regression techniques.²⁷ Clinical outcomes closest to 6 months were analyzed using meta-regression, with a permutation test (using 1000 Monte Carlo simulations, StataCorp) to calculate P values and to reduce the chance of spurious false-positive findings.²⁸ The amount of heterogeneity explained by the use of predictive covariates was examined by reductions in the I^2 inconsistency statistic within our model. Analyses were conducted using the “metan” and “metareg” commands in STATA version 8. To examine the relationship between the use of antidepressant medication and depression outcomes, we fitted a weighted Bayesian regression model, allowing for measurement error in both variables, using WinBUGS (Medical Research Council Biostatistics Unit, Cambridge, England).²⁹

CUMULATIVE META-ANALYSIS

We explored the evolution of evidence of the effectiveness of collaborative care over time using cumulative meta-analysis.³⁰




Figure 1. Random-effects meta-analysis of the effect of collaborative care on standardized depression outcomes at 6 months.




Figure 2. Begg funnel plot for studies reporting depression outcomes at 6 months.

Studies were sequentially added by year of publication to a random-effects model using the “metacum” user-written command in STATA version 8.

RESULTS

From 15 633 citations, 37 randomized studies met our inclusion criteria. Our review included 12 355 patients with depression randomized to receive either collaborative care or usual primary care.

EFFECT OF COLLABORATIVE CARE ON DEPRESSION OUTCOMES AT 6 MONTHS

Collaborative care had a clearly positive effect on standardized depression outcomes at 6 months compared with standard care (standardized mean difference [SMD], 0.25; 95% confidence interval [CI], 0.18-0.32). As anticipated, there was a moderate level of heterogeneity between studies ($I^2=52.8\%$) (Figure 1). There was no evidence of small study or publication bias²³ ($P=.14$) for these studies (Figure 2).

LONGER-TERM OUTCOMES

Eleven studies^{34,36,39,44,45,61-66} provided longer-term outcomes of up to 57 months⁶⁶ with collaborative care compared with standard care. The overall trend was for clinical improvement to be maintained at 12 months (SMD, 0.31; 95% CI, 0.01 to 0.53), 18 months (SMD, 0.25; 95% CI, 0.03 to 0.46), 24 months (SMD, 0.15; 95% CI, -0.03 to 0.34), and 5 years (SMD, 0.15; 95% CI, 0.001 to 0.30), although this failed to reach statistical significance at 24 months. There was substantial between-study heterogeneity ($I^2=84\%$ at 24 months) (Figure 3), but there were insufficient individual studies to explore the overall sources of this heterogeneity.

Since only a subset of studies reported longer-term outcome, we also tested for publication bias using the Egger test. None was evident at 12 months ($P=.09$), 18 months




Figure 3. Random-effects meta-analysis of longer-term outcome of collaborative care for depression.

($P = .41$), or 24 months ($P = .26$). Insufficient studies were available at 36 months or 5 years to exclude publication bias.

EXPLORATION OF CAUSES OF HETEROGENEITY

Sufficient study-level data were also available from most of the studies to allow the effect of the predictor variables to be entered into a meta-regression analysis.

Study Setting

Studies from the United States showed a strongly positive and statistically significant effect for collaborative care in improving depression outcomes at 6 months ($SMD_{US\ studies}, 0.27$; 95% CI, 0.22-0.33) and were subject to minimal between-study heterogeneity ($I^2_{US\ studies}, 5.4\%$), whereas non-US studies were nonsignificant in their pooled effect size ($SMD_{non-US\ studies}, 0.24$; 95% CI, -0.06 to 0.55) and were subject to substantial between-study heterogeneity ($I^2_{non-US\ studies}, 85.7\%$) (Figure 4). However, the pooled point estimate was essentially similar in US and non-US studies (meta-regression β , .01; 95% CI, -0.19 to 0.21; $P = .91$).

Content of Intervention

When we examined fidelity to the collaborative care model,⁹ all studies had a case manager, but several studies deviated from the model in that they did not have access to specialist input. These studies with lower fidel-

ity showed a lower pooled effect size and were more heterogeneous ($SMD_{low\ fidelity}, 0.187$; $I^2_{low\ fidelity}, 73.3\%$; $SMD_{high\ fidelity}, 0.30$; $I^2_{high\ fidelity}, 4.6\%$), although this difference was not significant (meta-regression β , 0.09; 95% CI, -0.08 to 0.25; $P = .29$; $I^2 = 50.7\%$). Two study-level variables, regular supervision and the mental health background of case managers, were significantly related to study effect size. The use of regular and planned supervision of the case manager, usually by a psychiatrist, was related to a more positive clinical outcome ($SMD_{usual\ supervision}, 0.29$; $SMD_{unplanned\ and\ ad\ hoc\ supervision}, 0.14$; meta-regression β , 0.15; 95% CI, -0.02 to 0.31; $P = .07$; $I^2 = 49.3\%$). Case managers with a specific mental health background also achieved better outcomes ($SMD_{CM\ mental\ health\ background}, 0.34$; $SMD_{CM\ non-mental\ health\ background}, 0.164$; meta-regression β , 0.18; 95% CI, 0.04-0.32; $P = .02$; $I^2 = 42.4\%$). However, the addition of a specific form of psychotherapy to medication management in collaborative care was not associated with any significantly increased effect size ($SMD_{psychotherapy + medication\ management}, 0.30$; $SMD_{medication\ management\ only}, 0.21$; meta-regression β , 0.10; 95% CI, -0.05 to 0.25; $P = .20$; $I^2 = 49.3\%$). Similarly, studies in which antidepressant medication was prescribed at entry to the trial were no more effective ($SMD_{antidepressants\ at\ entry}, 0.21$; $SMD_{antidepressants\ not\ consistently\ prescribed}, 0.30$; meta-regression β , -0.09; 95% CI, -0.24 to 0.06; $P = .23$; $I^2 = 50.7\%$). The number of case management sessions ranged from 2 to 14, but the number of sessions was not related to outcome (meta-regression β , 0.02; 95% CI, -0.008 to 0.04, $P = .19$; $I^2 = 50.9\%$) (Figure 5).




Figure 4. Random effects meta-regression analysis of the effect of non-US and US studies of collaborative care on depression outcomes at 6 months.




Figure 5. Meta-regression analysis of number of case management sessions vs depression outcomes at 6 months.




Figure 6. Bayesian weighted regression analysis of medication compliance vs depression outcomes at 6 months.

Compliance With Medication

From the weighted Bayesian regression model, compliance with medication predicted depression outcomes with credible certainty (slope coefficient, 0.19; 95% credible interval, 0.08-0.30) (Figure 6).

CUMULATIVE META-ANALYSIS OF OUTCOME AT 6 MONTHS

By plotting the emergence of collaborative care with time (Figure 7), it was clear that earlier trials of collaborative care fitting our inclusion criteria conducted in the late 1980s and early 1990s demonstrated a high degree of heteroge-




Figure 7. Cumulative random-effects meta-analysis of collaborative care vs standard care: depression outcomes at 6 months.

neity and a high percentage of negative results. More positive studies emerged in the mid 1990s, and a sufficient body of randomized evidence had accumulated by 2000 to demonstrate a reliable, consistent, and statistically significant benefit of collaborative care over standard care. Since 2000, the overall effect size for collaborative care has remained relatively stable within an effect size between SMD 0.20 and 0.29.

COMMENT

Our results confirm that collaborative care is effective in improving short-term outcomes in depression and, to our knowledge, summarize for the first time the emerging evidence of longer-term benefit. We believe ours is the most comprehensive review of this area to date and builds on previous work by correcting common methodological limitations and in exploring important sources of heterogeneity. The totality of evidence, when given using cumulative meta-analysis, shows that further trials are unlikely to overturn this positive result. Several areas deserve further consideration.

This is a substantial randomized evidence base and should help form a baseline for planning and delivering services. The magnitude of effect that can be expected in practice is moderate but comparable to other more intensive forms of face-to-face psychotherapy⁶⁷ and is likely to be cost-effective.⁶⁸ As a population-level strategy to improve the management of depression in a greater number of pa-

tients, collaborative care has the potential to substantially reduce the global burden of illness associated with depression.¹ In addition, a sustained benefit over the longer-term, even if this were of small to moderate magnitude, would also improve population well-being by reducing the number of days with depression and disability.⁶⁹

Collaborative care can be designed with varying levels of intensity and requires careful consideration in its implementation. Our review found important between-study heterogeneity, and we have used this variability to explore some of the issues in design and implementation that affect the magnitude of effectiveness in individual trials. This meta-regression analysis is exploratory and involves making observational associations within a randomized literature, and loses the power of causal inference.²⁸ The alternative approach is to plan prospective factorial trials with many arms to test all possible permutations of important aspects of the intervention. Such an approach is costly, time consuming, and unlikely to be undertaken, and in the absence of such trials meta-regression is a viable and efficient approach.

When we undertook our exploration of heterogeneity using meta-regression, we found that collaborative care facilitates improved concordance and that there was a dose-response relationship between medication use and improved depression outcomes. Other positive relationships included the use of regular and planned supervision, and case managers with a specific mental health background. These factors may serve to enhance thera-

peutic engagement and to work within a biopsychosocial model, where medication concordance and therapeutic alliance are seen as important in improving patient outcomes. The duration of case management and number of sessions were unrelated to effect size, and even brief interventions, such as telephone follow-up,³² were effective. The addition of psychotherapy was not generally associated with improved outcome. This finding should be interpreted with care because some trials offered patients a choice of either psychotherapy or medication enhancement before enrollment.⁷⁰ Improved outcomes in both interventions may in some way reflect a strong initial preference for one or the other of these treatments. Suggestive evidence emerged about the importance of fidelity to the collaborative care model offered by Katon et al.⁹ Studies with all 3 elements of collaborative care in place (a case manager, a primary care physician, and access to specialist input) tended to be more effective and were certainly more homogeneous than those studies with less model fidelity.

A further potential source of between-study heterogeneity might be the quality of usual care offered. Those studies with quality care in place might have less to gain from quality enhancements such as collaborative care, and vice versa. The quality of usual care is not described in any detail in the studies included in this review, and it was impossible to explore this further. This remains a limitation of the present review and is an unexplored alternative explanation for some of the associations we found.

A striking finding of our review was the presentation of this evidence, to our knowledge, for the first time, using cumulative meta-analysis. Sufficient randomized evidence had emerged by 2000 to demonstrate the effectiveness of collaborative care beyond conventional levels of statistical significance. Further and subsequent randomized trials have only sought to increase the precision of existing estimates of effectiveness, and it is unlikely that further randomized evidence will overturn this result. This begs the question of whether further trials of collaborative care are needed.

A recent editorial on the role of collaborative care concluded that "The evidence base is now sufficient for the emphasis to shift from research to dissemination and implementation."^{15(p250)} Our review supports that assertion, but only with certainty in the United States. Collaborative care studies conducted outside of the United States yielded nonsignificant results and were subject to a much larger degree of between-study heterogeneity compared with US studies. We believe there is a need for further research in the form of randomized controlled trials to examine how best this intervention can be designed and implemented in well-funded European health care systems and in less-well-funded systems in the developing world. Important evidence in Europe⁷¹ and in the developing world is beginning to emerge.³³ However, further research is needed to help clarify whether this system of care can be translated and implemented in settings other than US managed care.

Trials of collaborative care in the United States are targeted at high-risk groups such as patients with coexisting physical illness⁴⁶ or other common psychiatric problems such as anxiety,⁷² representing a greater desire to

understand how the effectiveness of collaborative care can be extended beyond depression. Compared with outcomes over the short term, there was still some uncertainty regarding the longer-term outcomes of collaborative care. Any further trials of collaborative care should also address the longer-term effects in addition to the longer-term cost-effectiveness of this approach.

Accepted for Publication: August 7, 2006.

Correspondence: Simon Gilbody, MBChB, MRCPsych, DPhil, Department of Health Sciences, University of York, York YO10 5DD, England (sg519@york.ac.uk).

Author Contributions: *Study concept and design:* Gilbody, Bower, and Richards. *Acquisition of data:* Gilbody, Bower, Fletcher, and Richards. *Analysis and interpretation of data:* Gilbody, Bower, Richards, and Sutton. *Drafting of the manuscript:* Gilbody and Sutton. *Critical revision of the manuscript for important intellectual content:* Gilbody, Bower, Fletcher, Richards, and Sutton. *Statistical analysis:* Gilbody and Sutton. *Obtained funding:* Gilbody and Richards. *Administrative, technical, and material support:* Gilbody, Bower, and Fletcher. *Study supervision:*

Financial Disclosure: None reported.

Acknowledgment: We thank the staff at the National Health Service Centre for Reviews and Dissemination for conducting the literature searches, and 2 anonymous peer reviewers for helpful comments.

REFERENCES

- Murray CJ, Lopez AD. *The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Disease, Injuries and Risk Factors in 1990*. Boston, Mass: Harvard School of Public Health on behalf of the World Bank, 1996.
- Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer HY. *Office of National Statistics: Psychiatric Morbidity Among Adults Living in Private Households, 2000*. London: Her Majesty's Stationery Office; 2001.
- Simon GE, Von Korff M. Recognition and management of depression in primary care. *Arch Fam Med*. 1995;4:99-105.
- Kessler D, Lloyd K, Lewis G, Gray DP. Cross-sectional study of symptom attribution and recognition of depression and anxiety in primary care. *BMJ*. 1999; 318:436-440.
- World Health Organization. *World Health Report 2001. Mental Health: New Understanding, New Hope*. Geneva, Switzerland: World Health Organization; 2001.
- Bower P, Gilbody S. Managing common mental health disorders in primary care: conceptual models and evidence base. *BMJ*. 2005;330:839-842.
- Cabana MD, Rushton JL, Rush AJ. Implementing practice guidelines for depression: applying a new framework to an old problem. *Gen Hosp Psychiatry*. 2002; 24:35-42.
- Bower P, Gask L. The changing nature of consultation-liaison in primary care: bridging the gap between research and practice. *Gen Hosp Psychiatry*. 2002; 24:63-70.
- Katon W, Von Korff M, Lin E, Simon GE. Rethinking practitioner roles in chronic illness: the specialist primary care physician and the practice nurse. *Gen Hosp Psychiatry*. 2001;23:138-144.
- Neumeyer-Gromen A, Lampert T, Stark K, Kallschnigg G. Disease management programs for depression: a systematic review and meta-analysis of randomized controlled trials. *Med Care*. 2004;42:1211-1221.
- Von Korff M, Goldberg D. Improving outcomes of depression: the whole process of care needs to be enhanced. *BMJ*. 2001;323:948-949.
- Gilbody S, Whitty P, Grimshaw J, Thomas R. Educational and organizational interventions to improve the management of depression in primary care: a systematic review. *JAMA*. 2003;289:3145-3151.
- Badamgarav E, Weingarten S, Henning J. Effectiveness of disease management programs in depression: a systematic review. *Am J Psychiatry*. 2003;160:2080-2090.
- Gensichen J, Beyer M, Muth C, Gerlach FM, Von Korff M, Ormel J. Case management to improve major depression in primary health care: a systematic review. *Psychol Med*. 2005;35:1-8.
- Simon G. Collaborative care for depression. *BMJ*. 2006;332:249-250.
- Peveler R, George C, Kinmonth AL, Campbell M, Thompson C. Effect of antidepressant drug counselling and information leaflets on adherence to drug treatment in primary care: randomised controlled trial. *BMJ*. 1999;319:612-615.
- Wells KB, Sherbourne C, Schoenbaum M, et al. Impact of disseminating quality

- improvement programmes for depression in managed primary care: a randomized controlled trial [published correction appears in *JAMA*. 2000;283:3204]. *JAMA*. 2000;283:212-220.
18. AHCPR Depression Guideline Panel. *Depression in Primary Care: Detection, Diagnosis, and Treatment*. Rockville, Md: US Dept of Health and Human Services, Public Health Service; 2000. Technical Report No. 5.
 19. Lipsey M, Wilson D. *Practical Meta-Analysis*. London, England: Sage Publications; 2001.
 20. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*. 1986; 7:177-188.
 21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ*. 2003;327:557-560.
 22. Begg CB. Publication bias. In: Cooper H, Hedges LV, eds. *The Handbook of Research Synthesis*. New York, NY: Russell Sage Foundation; 1994:399-409.
 23. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629-634.
 24. Bero L, Grilli R, Grimshaw J, Oxman A, eds. *The Cochrane Effective Practice and Organisation of Care Group (EPOC) module of the Cochrane database of systematic reviews [Cochrane Review on CD-ROM]*. Oxford, England: Cochrane Library, Update Software; 1998; issue 3. <http://www.interscience.wiley.com/cochrane/clabout/articles/EPOC/fram.html>. Accessed 15, 2006.
 25. Adams G, Gulliford MC, Ukoumunne OC, Eldridge S, Chinn S, Campbell MJ. Patterns of intra-cluster correlation from primary care research to inform study design and analysis. *J Clin Epidemiol*. 2004;57:784-793.
 26. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. *Stat Med*. 2002;21:2971-2980.
 27. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? *Stat Med*. 2002;21:1559-1573.
 28. Higgins JPT, Thompson SG. Controlling the risk of spurious findings from meta-regression. *Stat Med*. 2004;23:1663-1682.
 29. Spiegelhalter D, Thomas A, Best N, Lunn D. *WinBUGS User Manual, Version 2.0*. Cambridge, England: MRC Biostatistics Unit; 2004.
 30. Lau J, Antman EM, Jimenez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. *N Engl J Med*. 1992;327:248-254.
 31. Adler DA, Bungay KM, Wilson IB, et al. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. *Gen Hosp Psychiatry*. 2004;26:199-209.
 32. Akerblad AC, Bengtsson F, Ekselius L, von Knorring L. Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners. *Int Clin Psychopharmacol*. 2003;18:347-354.
 33. Araya R, Rojas G, Fritsch R, et al. Treating depression in primary care in low income women in Santiago, Chile: a randomised controlled trial. *Lancet*. 2003; 361:995-1000.
 34. Blanchard MR, Waterreus A, Mann AH. The effect of primary care nurse intervention upon older people screened as depressed. *Int J Geriatr Psychiatry*. 1995; 10:289-296.
 35. Brook O, van Hout H, Nieuwenhuysse H, Heerdink E. Impact of coaching by community pharmacists on the attitude of depressive primary care patients and acceptability to patients: a randomized controlled trial. *Eur Neuropsychopharmacol*. 2003;13:1-9.
 36. Bruce ML, Ten Have TF, Reynolds CF III, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients. *JAMA*. 2004; 291:1081-1091.
 37. Callahan CM, Hendrie HC, Dittus RS, Brater DC, Huis SL, Tierney WM. Improving treatment of late life depression in primary care: a randomized clinical trial. *J Am Geriatr Soc*. 1994;42:839-846.
 38. Capoccia KL, Boudreau DM, Blough DK, et al. Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. *Am J Health Syst Pharm*. 2004;61:364-372.
 39. Coleman EA, Grothaus LC, Sandhu N, Wagner EH. Chronic care clinics: a randomized controlled trial of a new model of primary care for frail older adults. *J Am Geriatr Soc*. 1999;47:775-783.
 40. Datto CJ, Thompson R, Horowitz D, Disbot M, Oslin DW. The pilot study of a telephone disease management program for depression. *Gen Hosp Psychiatry*. 2003;25:169-177.
 41. Dietrich AJ, Oxman TE, Williams JW Jr, et al. Going to scale: re-engineering systems for primary care treatment of depression. *Ann Fam Med*. 2004;2: 301-304.
 42. Finley P, Rens H, Gess S, Louie C. Case management of depression by clinical pharmacists in a primary care setting. *Formulary*. 1999;34:864-870.
 43. Hunkeler EM, Meresman JF, Hargreaves WA, et al. Efficacy of nurse telehealth care and peer support in augmenting treatment of depression in primary care. *Arch Fam Med*. 2000;9:700-708.
 44. Jarjoura D, Polen A, Baum E, Kropp D, Hetrick S, Rutecki G. Effectiveness of screening and treatment for depression in ambulatory indigent patients. *J Gen Intern Med*. 2004;19:78-84.
 45. Katon W, Rutter C, Ludman EJ, et al. A randomized trial of relapse prevention of depression in primary care. *Arch Gen Psychiatry*. 2001;58:241-247.
 46. Katon WJ, Von Korff M, Lin EHB, et al. The Pathways Study: a randomized trial of collaborative care in patients with diabetes and depression. *Arch Gen Psychiatry*. 2004;61:1042-1049.
 47. Katon W, Robinson P, Von Korff M, et al. A multifaceted intervention to improve treatment of depression in primary care. *Arch Gen Psychiatry*. 1996;53: 924-932.
 48. Katon W, Von Korff M, Lin E, et al. Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized general trial. *Arch Gen Psychiatry*. 1999;56:1109-1115.
 49. Katzelnick DJ, Simon GE, Pearson SD, et al. Randomized trial of a depression management program in high utilizers of medical care. *Arch Fam Med*. 2000; 9:345-351.
 50. Mann AH, Blizard R, Murray J. An evaluation of practice nurses working with general practitioners to treat people with depression. *Br J Gen Pract*. 1998; 48:875-879.
 51. Oslin DW, Sayers S, Ross J, et al. Disease management for depression and at risk drinking via telephone in an older population of veterans. *Psychosom Med*. 2003;65:931-937.
 52. Rickles N, Svarstad BL, Statz-Paynter JL, Taylor LV, Kobak KA. Pharmacists tele-monitoring of antidepressant use: effects on pharmacist-patient collaboration. *J Am Pharm Assoc*. 2005;45:344-353.
 53. Rost K, Nutting PA, Smith J, Werner J, Duan N. Improving depression outcomes in community primary care practice: a randomised trial of the QuEST intervention. *J Gen Intern Med*. 2001;16:143-149.
 54. Simon GE, Von Korff M, Ruter C, Wagner E. Randomised trial of monitoring feedback and management of care by telephone to improve treatment of depression in primary care. *BMJ*. 2000;320:550-554.
 55. Simon GE, Ludman EJ, Tutty S, Operskalski B, Korff MV. Telephone psychotherapy and telephone care management for primary care patients starting antidepressant treatment: a randomized controlled trial. *JAMA*. 2004;292: 935-942.
 56. Swindle RW, Rao JK, Helmy A, et al. Integrating clinical nurse specialists into the treatment of primary care patients with depression. *Int J Psychiatry Med*. 2003;33:17-37.
 57. Unutzer J, Katon W, Williams J, et al. Improving primary care for depression in late life: the design of a multicenter randomized trial. *Med Care*. 2001;39: 785-799.
 58. Whooley MA, Stone B, Soghikian K. Randomized trial of case-finding for depression in elderly primary care patients. *J Gen Intern Med*. 2000;15:293-300.
 59. Wilkinson G, Allen P, Marshall E. The role of the practice nurse in the management of depression in general practice: treatment adherence to antidepressant medication. *Psychol Med*. 1993;23:229-237.
 60. Blanchard MR, Waterreus A, Mann AH. Can a brief intervention have a longer-term benefit? the case of the research nurse and depressed older people in the community. *Int J Geriatr Psychiatry*. 1999;14:733-738.
 61. Hunkeler EM, Katon W, Tang L, et al. Long term outcomes from the IMPACT randomised trial for depressed elderly patients in primary care. *BMJ*. 2006; 332:259-263.
 62. Katon W, Russo J, Von Korff M, et al. Long-term effects of a collaborative care intervention in persistently depressed primary care patients. *J Gen Intern Med*. 2002;17:741-748.
 63. Lin EH, Simon GE, Katon WJ, et al. Can enhanced acute-phase treatment of depression improve long-term outcomes? a report of randomized trials in primary care. *Am J Psychiatry*. 1999;156:643-645.
 64. Rost K, Nutting P, Smith JL, Elliott CE, Dickinson M. Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care. *BMJ*. 2002;325:934-937.
 65. Sherbourne CD, Wells KB, Duan N, et al. Long-term effectiveness of disseminating quality improvement for depression in primary care. *Arch Gen Psychiatry*. 2001;58:696-703.
 66. Wells K, Sherbourne C, Schoenbaum M, et al. Five-year impact of quality improvement for depression: results of a group-level randomized controlled trial. *Arch Gen Psychiatry*. 2004;61:378-386.
 67. Churchill R, Hunot V, Corney R, et al. A systematic review of controlled trials of the effectiveness and cost-effectiveness of brief psychological treatments for depression. *Health Technol Assess*. 2001;5:1-173.
 68. Gilbody S, Bower P, Whitty P. The costs and consequences of enhanced primary care for depression: a systematic review of randomised economic evaluations. *Br J Psychiatry*. 2006;189:297-308.
 69. Lave JR, Frank RG, Schulberg HC, Kamlet MS. Cost-effectiveness of treatments for major depression in primary care practice. *Arch Gen Psychiatry*. 1998;55: 645-651.
 70. Wells KB. The design of Partners in Care: evaluating the cost effectiveness of improving care for depression in primary care. *Soc Psychiatry Psychiat Epidemiol*. 1999;34:20-29.
 71. Vergouwen AC, Bakker A, Burger H, Verheij TJ, Koerselman F. A cluster randomized trial comparing two interventions to improve treatment of major depression in primary care. *Psychol Med*. 2005;35:25-33.
 72. Roy-Byrne PP, Wagner AW, Schraufnagel TJ. Understanding and treating panic disorder in the primary care setting. *J Clin Psychiatry*. 2005;66(suppl 4): 16-22.